Allergopharma GmbH & Co. KG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Established
- 1969-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.allergopharma.de
Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical Trials
Phase 2
Terminated
- Conditions
- Allergic RhinoconjunctivitisHealthy Volunteers
- Interventions
- Drug: PlaceboBiological: Allergovit 6-grasses
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Target Recruit Count
- 158
- Registration Number
- NCT02297490
- Locations
- 🇨🇦
Inflamax Research INC, Mississauga, Ontario, Canada
Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis
Phase 2
Completed
- Conditions
- Allergic Rhinoconjunctivitis
- Interventions
- Drug: PlaceboBiological: rBet v1-FV
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Target Recruit Count
- 37
- Registration Number
- NCT01490411
- Locations
- 🇩🇪
Allergopharma GmbH & Co. KG, Hamburg, Reinbek, Germany
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
Phase 3
Completed
- Conditions
- RhinoconjunctivitisAllergic Asthma
- Interventions
- Drug: Grass pollen specific immunotherapyDrug: Placabo
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Target Recruit Count
- 195
- Registration Number
- NCT01353755
- Locations
- 🇩🇪
Allergopharma GmbH & Co. KG, Hamburg, Reinbek, Germany
Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative
Phase 2
Completed
- Conditions
- Allergic Rhinoconjunctivitis
- Interventions
- Other: PlaceboBiological: rBet v1-FV
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Target Recruit Count
- 14
- Registration Number
- NCT00841516
- Locations
- 🇸🇪
Prof. Dr. med. Sabina Rak, Gothenburg, Sweden
Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children
Phase 3
Completed
- Conditions
- Allergic Rhinoconjunctivitis
- Interventions
- Drug: PlaceboBiological: Grass pollen allergens in a water/glycerol solution
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Target Recruit Count
- 207
- Registration Number
- NCT00841256
- Locations
- 🇩🇪
Klinik für Paediatrie Universitätsmedizin Berlin, Berlin, Germany
Open Label Safety Study of a Birch Pollen Allergen Extract
Phase 2
Completed
- Conditions
- Rhinoconjunctivitis
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2013-03-11
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Target Recruit Count
- 73
- Registration Number
- NCT00818181
- Locations
- 🇩🇪
Prof. Dr. Nicolas Hunzelmann, Cologne, Germany
Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma
Phase 3
Completed
- Conditions
- Rhinoconjunctivitis
- Interventions
- Biological: AL0704rPBiological: Placebo
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Target Recruit Count
- 256
- Registration Number
- NCT00671268
- Locations
- 🇩🇪
Allergopharma GmbH & Co. KG, Reinbek, Germany
Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens
Phase 2
Completed
- Conditions
- Type I-Allergy
- Interventions
- Biological: rPhleumDrug: placebo
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Target Recruit Count
- 50
- Registration Number
- NCT00666341
- Locations
- 🇩🇪
Prof. Dr. med. Ludger Klimek, Wiesbaden, Baden-W., Germany
Design of Optimally-diagnostic Skin Test Solutions for Diagnosis of Sensitisation to a Pollen and Dust Mite Mixture.
Phase 4
Completed
- Conditions
- Type I Allergy
- Interventions
- Other: Skin Prick Test
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Registration Number
- NCT00665483
- Locations
- 🇩🇪
Klinikum Darmstadt, Darmstadt, Hessen, Germany
Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation
Phase 3
Completed
- Conditions
- ConjunctivitisAllergyRhinitis
- Interventions
- Biological: Allerslit forte
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Target Recruit Count
- 126
- Registration Number
- NCT00623701
- Locations
- 🇩🇪
Prof. Kristian Reich, MD, Hamburg, Germany
© Copyright 2025. All Rights Reserved by MedPath